Hem › Triplenegativ bröstcancer › Michigan › Grand Rapids
Kliniska studier för Triplenegativ bröstcancer i Grand Rapids, MI
15 studier för Triplenegativ bröstcancer söker deltagare vid platser i och runt Grand Rapids (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekryterarFas 1
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekryterarFas 1
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekryterarFas 1/2
- BAMF Health, Grand Rapids
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekryterarFas 3
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekryterarFas 1
- BAMF Health, Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
RekryterarFas 1
- START Midwest, Grand Rapids
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekryterarFas 3
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekryterarFas 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekryterarFas 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RekryterarFas 1/2
- Research Site, Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- START Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekryterarFas 1/2
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RekryterarFas 1
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
RekryterarFas 1
- START Midwest, LLC, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekryterarFas 1
- START Midwest /ID# 248685, Grand Rapids
Triplenegativ bröstcancer-studier i andra städer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andra studier i Grand Rapids
- Icke-småcellig lungcancer44 studier
- Kolorektal cancer40 studier
- Cancer (alla typer)28 studier
- Bröstcancer26 studier
- Äggstockscancer24 studier
- Metastaserande cancer22 studier
- Prostatacancer19 studier
- Endometriecancer18 studier
- Magsäckscancer18 studier
- Bukspottkörtelcancer18 studier
- Melanom17 studier
- Plattenepitelcancer i huvud och hals15 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.